Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.

Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults

(2021) Brett D. M. Jones et al.   JAMA Network Open

Intravenous arketamine for treatment-resistant depression: open-label pilot study

(2020) Gustavo C. Leal et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

(2020) Ziad Saad et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

(2019) Vanina Popova et al.   AMERICAN JOURNAL OF PSYCHIATRY

Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study

(2019) Fernanda S. Correia-Melo et al.   JOURNAL OF AFFECTIVE DISORDERS

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

(2018) Panos Zanos et al.   PHARMACOLOGICAL REVIEWS

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

(2018) Nolan R. Williams et al.   AMERICAN JOURNAL OF PSYCHIATRY

Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

(2018) Maurizio Fava et al.   MOLECULAR PSYCHIATRY

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

(2016) Jaskaran B. Singh et al.   BIOLOGICAL PSYCHIATRY

Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression

(2012) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY